Brown Advisory Inc. grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 15.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,067 shares of the medical research company’s stock after purchasing an additional 139 shares during the quarter. Brown Advisory Inc.’s holdings in Bio-Rad Laboratories were worth $248,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc grew its holdings in shares of Bio-Rad Laboratories by 2.0% during the third quarter. Vanguard Group Inc now owns 1,832,968 shares of the medical research company’s stock worth $573,701,000 after buying an additional 35,261 shares during the last quarter. Stevens Capital Management LP grew its holdings in shares of Bio-Rad Laboratories by 62.6% during the third quarter. Stevens Capital Management LP now owns 16,893 shares of the medical research company’s stock worth $5,287,000 after buying an additional 6,505 shares during the last quarter. CenturyLink Investment Management Co grew its holdings in shares of Bio-Rad Laboratories by 15.9% during the fourth quarter. CenturyLink Investment Management Co now owns 4,266 shares of the medical research company’s stock worth $991,000 after buying an additional 586 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Bio-Rad Laboratories by 5.5% during the third quarter. Thrivent Financial for Lutherans now owns 4,868 shares of the medical research company’s stock worth $1,524,000 after buying an additional 253 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in shares of Bio-Rad Laboratories by 0.3% during the third quarter. BlackRock Inc. now owns 1,867,884 shares of the medical research company’s stock worth $584,627,000 after buying an additional 6,197 shares during the last quarter. 63.65% of the stock is currently owned by institutional investors.

Shares of NYSE:BIO opened at $302.42 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.51 and a quick ratio of 3.20. The stock has a market capitalization of $9.22 billion, a P/E ratio of 52.60, a PEG ratio of 2.86 and a beta of 1.25. Bio-Rad Laboratories, Inc. has a 52 week low of $220.05 and a 52 week high of $345.15.

A number of equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $360.00 price objective for the company in a research report on Wednesday, March 6th. Barclays upgraded shares of Bio-Rad Laboratories from an “equal weight” rating to an “overweight” rating and set a $315.00 price objective for the company in a research report on Thursday, January 3rd. Finally, Deutsche Bank raised their price objective on shares of Bio-Rad Laboratories from $330.00 to $350.00 and gave the company a “buy” rating in a research report on Friday, March 1st. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $359.17.

WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/brown-advisory-inc-raises-holdings-in-bio-rad-laboratories-inc-bio/2922958.html.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

See Also: Municipal Bonds

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.